Independent and cooperative roles of tumor necrosis factor-α, nuclear factor-γB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells

Cancer Science

Volumn 101, Issue 1, 2010, Pages 103-111

  Graham, Tisheeka R ^a   Agrawal, Krishna C ^b   Abdel Mageed, Asim B ^a,b  

^a Department of Urology ^*  (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOPONTIN; SMAD PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE FUNCTION; GENETIC REGULATION; HUMAN; HUMAN CELL; METASTASIS; METASTASIS POTENTIAL; MINERALIZATION; MOLECULAR MIMICRY; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; MALE; NEOPLASM METASTASIS; NF-KAPPA B; OSTEOBLASTS; PROSTATIC NEOPLASMS; RANK LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71849089013     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01356.x     Document Type: Article

References (71)

1. Bubendorf L, Schopfer A, Wagner U. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Human Pathol 2000, 31:578-83.
2. May M, Ghosh S. Signal transduction through NF-γB. Immunol Today 1998, 19:80-8.
3. Andela VB, Gordon AH, Zotalis G. NF-γB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003, 415(Suppl.):S75-85.
4. Baichwal V, Baeuerle P. Apoptosis: activate NF-γB or die? Curr Biol 1997, 7:R94-6.
5. Feng X, Xia L, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev 1998, 12:2153-63.
6. Jilka RL, Takahashi K, Munshi M. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow: Evidence for autonomy from factors released during bone resorption. J Clin Invest 1998, 101:1942-59.
7. Komori T, Yagi H, Nomura S. Targeted disruption of cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-64.
8. Miyazawa K, Shinozaki M, Hara T. Two major Smad pathways in TGF-β superfamily signaling. Genes Cells 2002, 7:1191-204.
9. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000, 57:2207-14.
10. Oft M. TGF-β signaling is necessary for carcinoma cell invasiveness. Curr Biol 1998, 8:1243-52.
11. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005, 328:651-7.
12. Kim IY, Lee DH, Ahn HJ. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 2000, 60:2840-4.
13. Valdimarsdottir G, Goumans MJ, Rosendahl A. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002, 106:2263-70.
14. Russell PJ. Growth factor involvement in progression of prostate cancer. Clin Chem 1998, 44:705-23.
15. Autzen P, Robson CN, Bjartell A. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998, 78:1219-23.
16. Ide H, Yoshida T, Matsumoto N. Growth regulation of human prostate cancer cells by bone morphogenetic protein 2. Cancer Res 1997, 57:5022-7.
17. Thomas BG, Hamdy FC. Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 2000, 3:283-5.
18. Thomas R, Anderson WA, Raman V. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse protein in mouse prostate. Prostate 1998, 37:236-45.
19. Ritchie CK. The effects of growth factors associated with osteoblasts on prostate cancer proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997, 138:1145-50.
20. Brubaker KD, Corey E, Brown LG. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004, 91:151-60.
21. Bentley H, Handley F, Hart KA. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992, 66:1159-63.
22. Haudenschild DR, Palmer SM, Moseley TA. Bone morphogenetic protein (BMP-6) signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004, 64:8276-84.
23. Fisher JL. An in vivo model of prostate cancer growth and invasion in bone. Cell Tissue Res 2002, 307:337-45.
24. Barrack E. TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997, 3331:61-70.
25. Maliakal J, Asahina I, Hauschka P. Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma cells. Growth Factors 1994, 11:227-34.
26. Kim I, Lee DH, Ahn HJ. Expression of bone morphogenetic protein receptors type IA,-IB, and -II in human prostate cancer cells. Oncogene 2004, 23:7651-9.
27. Graham TR, Odero-Marah VA, Chung LW. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-γB in metastatic prostate cancer cells. Prostate 2009, 69:168-80.
28. Wu S, Flint JK, Rezvani G, De Luca F. Nuclear factor-γB p65 facilitates longitudinal bone growth by inducing growth plate chondrocyte proliferation and differentiation and by preventing apoptosis. J Biol Chem 2007, 282:33698-706.
29. Flynn V, Ramanitharan A, Moparty K. Adenovirus-mediated inhibition of NF-γB confers chemosensitization and apoptosis in prostate cancer cells. Int J Oncol 2003, 23:317-23.
30. Kitagawa Y, Dai J, Zhang J. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005, 65:10921-9.
31. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001, 27:187-92.
32. Keller E, Zhang J, Cooper C. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001, 20:333-49.
33. Suh J, Payvandi F, Edelstein L. Mechanisms of constitutive NF-γB activation in human prostate cancer cells. Prostate 2002, 52:183-200.
34. Lin D, Tarnowski C, Zhang J. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001, 47:212-21.
35. Luque I. Rel/NF-γB and IγB factors in oncogenesis. Semin Cancer Biol 1997, 8:103-11.
36. Orlowski RZ, Baldwin AS. NF-γB as a therapeutic target in cancer. Trends Mol Med 2002, 8:385-9.
37. Huang S, Pettaway CA, Uehara H. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20:4188-97.
38. Lindholm P, Bub J, Kaul S. The role of constitutive NF-γB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2001, 18:471-9.
39. Merkel KD, Erdmann JM, McHugh KP. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999, 154:203-10.
40. Pacifici R, Brown C, Puscheck E. Effect of surgical menopause and estrogenreplacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 1991, 88:5134-8.
41. De Vita F, Orditura M, Infusino S. Increased serum levels of tumor necrosis factor-alpha are correlated to soluble intracellular adhesion molecule-1 concentrations in non-small lung cancer patients. Int J Mol Med 1998, 1:605-8.
42. Wu S, Boyer CM, Whitaker RS. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993, 53:1939-44.
43. Van Antwerp DJ, Martin SJ, Kafri T. Suppression of TNF-α induced apoptosis by NF-γB. Science 1996, 274:787-9.
44. Barnes P, Karin M. Nuclear Factor-γB-A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-71.
45. Keller E, Brown J. Prostate cancer bone metastasis promotes both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91:718-29.
46. Harris SE, Harris MA, Mahy P. Expression of bone morphogenetic proteins messenger RNA by normal rat and human prostate and prostate cancer cells. Prostate 1994, 24:204-11.
47. Lee Y, Schwarz E, Davies M. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003, 21:62-72.
48. Leivonen SK, Ala-Aho R, Koli K. Activation of Smad signaling enhances collagenase-3 (MMP-13 expression) expression and invasion of head and neck squamous carcinoma cells. Oncogene 2006, 25:2588-600.
49. Feeleya BT, Kreneka L, Liu N. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38:154-66.
50. Baade RT, Utne HR, Brenne AT. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004, 23:3024-32.
51. Rothhammer T, Poser I, Soncin F. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005, 65:448-56.
52. Mayer H, Scutt AM, Ankenbauer T. Subtle differences in the mitogenic effects of recombinant human bone morphogenetic proteins-2 to -7 on DNA synthesis on primary bone-forming cells and identification of BMP-2/4 receptor. Calcif Tissue Int 1996, 58:249-55.
53. Gilboa L, Nohe A, Geissendorfer T. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 2000, 11:1023-35.
54. Nohe A, Hassel S, Ehrlich M. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002, 277:5330-8.
55. Gordon KJ, Kirkbride KC, How T. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 2009, 30:238-48.
56. Langenfeld EM, Calvano SE, Abou-Nukta F. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003, 24:1445-54.
57. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992, 31:160-7.
58. Willette RN, Lysko PG, Anderson KM. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 1999, 36:120-5.
59. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-61.
60. Koutsiliens M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993, 13:443-9.
61. Mundy G. Metastasis to bone: causes, consequences and therapeutics opportunities. Nature 2002, 2:584-93.
62. Thalmann GN, Sikes RA, Devoll RE. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999, 5:2271-7.
63. Weismann D, Briese J, Niemann J. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 2009, 218:232-40.
64. Fong Y-C, Liu S-C, Huang C-Y. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappa B-dependent pathway. Lung Cancer 2009, 64:263-70.
65. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
66. Roato I, Grano M, Brunetti G. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005, 19:228-30.
67. Kobayashi K, Takahashi N, Jimi E. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKLRANK interaction. J Exp Med 2000, 191:275-86.
68. Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003, 21:73-80.
69. Ding J, Ghali O, Lencel P. TNF-α and IL-1β inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 2009, 84:499-504.
70. Susperregui ARG, Viñals F, Ho PWM. BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells. J Cell Physiol 2008, 216:144-52.
71. Hofbauer LC, Dunstan CR, Spelsberg TC. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998, 250:776-81.